PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26667237-3 2016 Reticulocyte hemoglobin equivalent (Ret-He) may be useful for assessing iron status. Iron 72-76 ret proto-oncogene Homo sapiens 0-3 28704831-2 2017 Due to the short life span of reticulocytes, Ret-He reflects current iron availability for erythropoiesis more accurately than other common erythrocyte indices. Iron 69-73 ret proto-oncogene Homo sapiens 45-48 27805332-1 2016 AIM: To evaluate reticulocyte hemoglobin (RET-He) vis-a-vis serum ferritin as a marker of bone marrow iron store in iron deficiency anemia (IDA). Iron 102-106 ret proto-oncogene Homo sapiens 42-45 31556266-1 2017 Aim: To evaluate reticulocyte hemoglobin (RET-Hb) vis-a-vis immature reticulocyte fraction (IRF) as an earliest indicator of response to iron therapy in iron deficiency anemia (IDA), by assessing change in RET-He and IRF at 48 hours after initiation of intravenous iron therapy. Iron 137-141 ret proto-oncogene Homo sapiens 42-45 31556266-1 2017 Aim: To evaluate reticulocyte hemoglobin (RET-Hb) vis-a-vis immature reticulocyte fraction (IRF) as an earliest indicator of response to iron therapy in iron deficiency anemia (IDA), by assessing change in RET-He and IRF at 48 hours after initiation of intravenous iron therapy. Iron 153-157 ret proto-oncogene Homo sapiens 42-45 31556266-10 2017 RET-He and IRF increased significantly at 48 hours after initiation of intravenous iron therapy (post therapy) as compared to baseline (pre therapy) in both the two groups as well when all patients were considered together. Iron 83-87 ret proto-oncogene Homo sapiens 0-3 31556266-13 2017 Conclusion: RET-Hb, a real time indicator of iron supply (hemoglobinization) to the developing RBC"s, is the earliest marker of response to iron therapy as compared to IRF (representative of reticulocyte count). Iron 45-49 ret proto-oncogene Homo sapiens 12-15 31556266-13 2017 Conclusion: RET-Hb, a real time indicator of iron supply (hemoglobinization) to the developing RBC"s, is the earliest marker of response to iron therapy as compared to IRF (representative of reticulocyte count). Iron 140-144 ret proto-oncogene Homo sapiens 12-15 28299633-2 2017 The recent development of automated systems for hematology analysis has made it possible to measure reticulocyte hemoglobin equivalent (RET-He), which is thought to reflect iron content in reticulocytes, in the same sample used for complete blood count tests. Iron 173-177 ret proto-oncogene Homo sapiens 136-139 28299633-12 2017 RET-He changed in parallel with changes in Hb during iron administration for 21 IDA patients. Iron 53-57 ret proto-oncogene Homo sapiens 0-3 28450652-1 2017 AIM: to evaluate the correlation and the concordance between reticulocyte hemoglobin equivalent (RET-He) and reticulocyte hemoglobin content (CHr) as well as to obtain the cut-off value of RET-He as the target of iron supplementation in chronic kidney disease (CKD) patients undergoing hemodialysis. Iron 213-217 ret proto-oncogene Homo sapiens 189-192 27805332-10 2016 RET-He was the only significant predictor of bone marrow iron stores (at P < 0.05). Iron 57-61 ret proto-oncogene Homo sapiens 0-3 27805332-13 2016 CONCLUSIONS: RET-He correlated significantly with serum ferritin and is also a better predictor of bone marrow iron stores than the latter. Iron 111-115 ret proto-oncogene Homo sapiens 13-16 26667237-8 2016 CONCLUSIONS: Ret-He is a more relevant marker of iron status than ferritin and TSAT. Iron 49-53 ret proto-oncogene Homo sapiens 13-16 22440657-3 2011 OBJECTIVE: To evaluate the ability of Reticulocyte Hemoglobin Equivalent (RET-He) to predict iron deficiency, taking as a reference standard to the increase of hemoglobin in response to iron intake. Iron 93-97 ret proto-oncogene Homo sapiens 74-77 27141568-1 2016 INTRODUCTION: Reticulocyte hemoglobin equivalent (RET-He) is a new parameter for evaluating iron status. Iron 92-96 ret proto-oncogene Homo sapiens 50-53 27141568-2 2016 This study aims to assess diagnostic value and investigate RET-He as early predictor of response to intravenous iron supplementation. Iron 112-116 ret proto-oncogene Homo sapiens 59-62 27141568-10 2016 CONCLUSION: RET-He is a useful marker of iron deficiency and early predictor of response to intravenous iron supplementation in regular hemodialysis patients. Iron 41-45 ret proto-oncogene Homo sapiens 12-15 24781685-0 2014 The value of Ret-Hb and sTfR in the diagnosis of iron depletion in healthy, young children. Iron 49-53 ret proto-oncogene Homo sapiens 13-16 24781685-1 2014 OBJECTIVES: Reticulocyte hemoglobin (Ret-Hb) content and soluble transferrin receptor (sTfR) are described as promising biomarkers in the analysis of iron status. Iron 150-154 ret proto-oncogene Homo sapiens 12-15 24781685-3 2014 We hypothesized that young children to iron depletion, using the WHO cutoff of ferritin <12 mug/l, would have lower Ret-Hb and higher sTfR concentrations compared to children with a ferritin >=level 12 mug/l. Iron 39-43 ret proto-oncogene Homo sapiens 119-122 24781685-6 2014 RESULTS: We showed that concentrations of Ret-Hb and sTfR are similar in children with and without iron depletion. Iron 99-103 ret proto-oncogene Homo sapiens 42-45 24781685-9 2014 CONCLUSIONS: Our results showed that the discriminative value of Ret-Hb and sTfR for the detection of iron depletion is limited. Iron 102-106 ret proto-oncogene Homo sapiens 65-68 23355942-4 2012 The aim of this study was to establish short-term effects of iron supplementation on the hemoglobin content of reticulocytes (Ret-He) and red blood cells (RBC-He) in case of suspected iron deficient erythropoiesis (IDE) in the third trimester of pregnancy. Iron 61-65 ret proto-oncogene Homo sapiens 126-129 23355942-6 2012 After iron supplementation, reticulocyte counts increased from 0.061+-0.015x10(12)/L to 0.079+-0.026x10(12)/L and Ret-He increased from 23.6+-2.8 pg to 28.3+-2.6 pg (P=<0.001). Iron 6-10 ret proto-oncogene Homo sapiens 114-117 23193472-3 2012 In addition to the usual iron parameters, the iron status of erythrocytes can be determined by measuring reticulocyte hemoglobin (RET-He). Iron 46-50 ret proto-oncogene Homo sapiens 130-133 21815478-2 2011 The reticulocyte hemoglobin equivalent (RET-He) is an indirect measure of the functional iron available for the erythropoiesis over the previous 2-3 days. Iron 89-93 ret proto-oncogene Homo sapiens 40-43 21815478-6 2011 Of 26 patients receiving post-PABD iron replacement, 8 who had already showed low RET-He levels at PABD developed statistically significant reduction in hemoglobin levels after PABD despite adequate iron replacement, indicating that the 8 patients had iron deficiency prior to PABD. Iron 35-39 ret proto-oncogene Homo sapiens 82-85 22440657-10 2011 CONCLUSIONS: According to these results it could consider to Ret-He and the Ret-He/IST combination of clinical utility for the identification of the iron deficit in patients in chronic haemodialysis. Iron 149-153 ret proto-oncogene Homo sapiens 61-64 22440657-10 2011 CONCLUSIONS: According to these results it could consider to Ret-He and the Ret-He/IST combination of clinical utility for the identification of the iron deficit in patients in chronic haemodialysis. Iron 149-153 ret proto-oncogene Homo sapiens 76-79 19624802-13 2010 Iron supplements given to the patients with low TSAT or ferritin, RET-He responded within 2 weeks, and this seemed to be a potential advantage of using RET-He in the estimation of iron status. Iron 180-184 ret proto-oncogene Homo sapiens 152-155 19624802-2 2010 The cellular iron status of the patients can be determined from the recently available measurement of reticulocyte hemoglobin equivalent (RET-He). Iron 13-17 ret proto-oncogene Homo sapiens 138-141 19624802-6 2010 Secondly, we investigated the changes in RET-He during iron supplementation for iron-deficient patients to determine whether this marker is a prospective and reliable indicator of iron sufficiency. Iron 55-59 ret proto-oncogene Homo sapiens 41-44 19624802-13 2010 Iron supplements given to the patients with low TSAT or ferritin, RET-He responded within 2 weeks, and this seemed to be a potential advantage of using RET-He in the estimation of iron status. Iron 0-4 ret proto-oncogene Homo sapiens 66-69 19624802-13 2010 Iron supplements given to the patients with low TSAT or ferritin, RET-He responded within 2 weeks, and this seemed to be a potential advantage of using RET-He in the estimation of iron status. Iron 0-4 ret proto-oncogene Homo sapiens 152-155 19624802-14 2010 RET-He is a new parameter, equivalent value to CHr, and is easily measurable on the widely spread and popular blood cell counter and is a sensitive and specific marker of iron status in dialysis patients. Iron 171-175 ret proto-oncogene Homo sapiens 0-3 20415234-2 2010 Cellular iron status can be determined by the recently available method of measuring the reticulocyte hemoglobin equivalent (RET-He). Iron 9-13 ret proto-oncogene Homo sapiens 125-128 20606413-9 2010 CONCLUSION: Fluctuations in Ret-He and DF-HYPO XE have to be taken into account when these parameters are used for the assessment of iron-deficient states. Iron 133-137 ret proto-oncogene Homo sapiens 28-31 19344417-8 2009 Serum hepcidin, Ret-H(e) and Delta-H(e) (Ret-H(e) minus RBC-H(e)) are promising biomarkers to select those individuals who will benefit from iron supplements in malaria endemic regions, while the sTfR/log ferritin ratio should be used with caution to assess iron status during malaria. Iron 141-145 ret proto-oncogene Homo sapiens 16-19 19344417-8 2009 Serum hepcidin, Ret-H(e) and Delta-H(e) (Ret-H(e) minus RBC-H(e)) are promising biomarkers to select those individuals who will benefit from iron supplements in malaria endemic regions, while the sTfR/log ferritin ratio should be used with caution to assess iron status during malaria. Iron 141-145 ret proto-oncogene Homo sapiens 41-44 19344417-8 2009 Serum hepcidin, Ret-H(e) and Delta-H(e) (Ret-H(e) minus RBC-H(e)) are promising biomarkers to select those individuals who will benefit from iron supplements in malaria endemic regions, while the sTfR/log ferritin ratio should be used with caution to assess iron status during malaria. Iron 258-262 ret proto-oncogene Homo sapiens 41-44 18027835-4 2008 The reticulocyte hemoglobin content (CHr or Ret-He) provides an indirect measure of the functional iron available for new red blood cell production over the previous 3-4 days. Iron 99-103 ret proto-oncogene Homo sapiens 44-47 15229154-0 2004 Potential utility of Ret-Y in the diagnosis of iron-restricted erythropoiesis. Iron 47-51 ret proto-oncogene Homo sapiens 21-24 16999719-7 2006 Ret He is a reliable marker of cellular hemoglobin content and can be used to identify the presence of iron-deficient states. Iron 103-107 ret proto-oncogene Homo sapiens 0-3 17175894-2 2006 Reticulocyte hemoglobin content (RET-He) is considered to be an actual indicator reflecting functional iron availability for erythropoiesis. Iron 103-107 ret proto-oncogene Homo sapiens 33-36 16232085-10 2005 Correlations of biochemical iron markers with RET-H(e) were as weak as with CHr in patients with ACD and acute phase response. Iron 28-32 ret proto-oncogene Homo sapiens 46-49 16232085-11 2005 In a diagnostic plot to identify iron status, RET-H(e) could replace CHr without any loss of sensitivity or specificity. Iron 33-37 ret proto-oncogene Homo sapiens 46-49 16232085-15 2005 RET-H(e) is as valuable as CHr for the diagnosis of iron-restricted erythropoiesis. Iron 52-56 ret proto-oncogene Homo sapiens 0-3 16232085-16 2005 The combination of RET-H(e) and the sTfR-F index in a diagnostic plot offers an attractive tool for the evaluation of iron status and identification of the progression of ID. Iron 118-122 ret proto-oncogene Homo sapiens 19-22 17353176-11 2007 In comparison with CHr, the value of 30.5 pg for RET-He appeared to be the best cut-off point with a very good sensitivity and specificity to determine patients needing iron supplementation. Iron 169-173 ret proto-oncogene Homo sapiens 49-52 17353176-12 2007 Our study showed an excellent diagnostic efficiency of RET-He to evaluate patients needing iron support and demonstrated a strict correspondence between the classic CHr and the new Ret-He. Iron 91-95 ret proto-oncogene Homo sapiens 55-58 35443540-3 2022 RET-He measure the recent functional availability of iron and the correlation well with iron deficient / restricted erythropoiesis, and it is not affected by infection and inflammation related to cancer so it can be useful marker to rapidly rule out iron deficiency in cancer patients. Iron 53-57 ret proto-oncogene Homo sapiens 0-3 34913799-6 2021 Ret-He and IRF have been established as the marker of iron deficiency and iron-deficiency anaemia in different age groups and as a marker of response to iron therapy. Iron 153-157 ret proto-oncogene Homo sapiens 0-3 15080300-7 2004 RET-Y is correlated closely with CHr and is useful for diagnosis and early monitoring after the administration of intravenous iron. Iron 126-130 ret proto-oncogene Homo sapiens 0-3 34107639-7 2021 Immature reticulocyte fraction (IRF) and reticulocyte hemoglobin equivalent (Ret-He) were significantly higher in the iron deficient group as compared to alpha and beta thalassemia. Iron 118-122 ret proto-oncogene Homo sapiens 77-80 34107639-9 2021 Sig-nificantly reduced levels of Ret-He were observed in alpha thalassemia and beta thalassemia in comparison to iron deficient group. Iron 113-117 ret proto-oncogene Homo sapiens 33-36 34107639-10 2021 While iron deficient group was characterized by increased values of RDW-SD, RDW-CV, IRF, and Ret-He. Iron 6-10 ret proto-oncogene Homo sapiens 93-96 35443540-3 2022 RET-He measure the recent functional availability of iron and the correlation well with iron deficient / restricted erythropoiesis, and it is not affected by infection and inflammation related to cancer so it can be useful marker to rapidly rule out iron deficiency in cancer patients. Iron 88-92 ret proto-oncogene Homo sapiens 0-3 35443540-10 2022 Observation: At a cut off of 28.4 pg, RET-He achieved sensitivity of 96.77 % and specificity of 81.66% with NPV of 99.3% and PPV of 49.2% for iron deficient state in cancer patients. Iron 142-146 ret proto-oncogene Homo sapiens 38-41 35443540-13 2022 Conclusion: RET-He is better indicator of IDA in cancer patients as compared to other conventional methods of diagnosing IDA.This study also revealed a direct correlation between RET-He and bone marrow iron stores. Iron 202-206 ret proto-oncogene Homo sapiens 12-15 35443540-13 2022 Conclusion: RET-He is better indicator of IDA in cancer patients as compared to other conventional methods of diagnosing IDA.This study also revealed a direct correlation between RET-He and bone marrow iron stores. Iron 202-206 ret proto-oncogene Homo sapiens 179-182 33952394-10 2021 CONCLUSION: Data from CBC and RET-He can identify patients with IDA, determine need for and responsiveness to intravenous iron, and reduce time for therapeutic decisions. Iron 122-126 ret proto-oncogene Homo sapiens 30-33 33012780-1 2021 OBJECTIVE: To determine why serum ferritin and reticulocyte hemoglobin (RET-He), drawn to assess neonatal iron sufficiency, sometimes have markedly discordant results. Iron 106-110 ret proto-oncogene Homo sapiens 72-75 33565438-6 2020 Ret-HE mean value in anemic patients was (25.84 +- 4.23 pg) and had good correlation (P <0.001) between Ret-HE, serum iron, ferritin, transferrin, and transferin saturation in dialysis patients. Iron 118-122 ret proto-oncogene Homo sapiens 0-3 33231049-3 2020 The reticulocyte hemoglobin equivalent (RET-He) is a marker that is not altered by inflammatory conditions and directly reflects iron availability in the bone marrow. Iron 129-133 ret proto-oncogene Homo sapiens 40-43 33104871-4 2020 The RET-He is a cost-effective parameter for the diagnosis and monitoring of the iron supply for erythropoiesis. Iron 81-85 ret proto-oncogene Homo sapiens 4-7 32950976-3 2020 Reticulocyte haemoglobin (Ret-He) depends on available iron in blood, indirectly regulated by hepcidin. Iron 55-59 ret proto-oncogene Homo sapiens 0-3 31851071-0 2020 Reticulocyte Hemoglobin Content (Ret He): A Simple Tool for Evaluation of Iron Status in Childhood Cancer. Iron 74-78 ret proto-oncogene Homo sapiens 0-3 31851071-11 2020 A trial of oral iron in patients with low Ret He may be useful to correct the associated anemia. Iron 16-20 ret proto-oncogene Homo sapiens 42-45 32709979-3 2021 We defined iron-limited erythropoiesis by a RET-He <5th percentile lower reference interval (<28 pg). Iron 11-15 ret proto-oncogene Homo sapiens 44-47 30968565-11 2019 CONCLUSION: In cost constraints settings, a simple investigation like Ret He alone or with serum ferritin can help us to diagnose and differentiate between the different types of anemia accompanying rheumatological disorders without doing other serum iron studies and expensive tests like transferrin receptor protein which are not readily available. Iron 251-255 ret proto-oncogene Homo sapiens 70-73 31825671-11 2020 Ret-He and Hypo-He can be used to assess iron supply for erythropoiesis in patients with IBD, to evaluate long-term (Hypo-He) and short-term (Ret-He) periods. Iron 41-45 ret proto-oncogene Homo sapiens 0-3 31350450-1 2019 OBJECTIVE: The reticulocyte index reticulocyte hemoglobin equivalent (Ret-He) was evaluated as a marker of iron status. Iron 107-111 ret proto-oncogene Homo sapiens 70-73 31350450-7 2019 CONCLUSION: Ret-He values showed a slow uptrend with enteral iron supplementation following an initial decrease, suggesting that neonates are able to improve their iron sufficiency status with supplementation. Iron 61-65 ret proto-oncogene Homo sapiens 12-15 31350450-7 2019 CONCLUSION: Ret-He values showed a slow uptrend with enteral iron supplementation following an initial decrease, suggesting that neonates are able to improve their iron sufficiency status with supplementation. Iron 164-168 ret proto-oncogene Homo sapiens 12-15 31662016-3 2021 Reticulocyte hemoglobin content (RET-He), a measure of iron deficiency, has not been well evaluated prior to discharge in premature infants.Objectives: Our objectives were to evaluate RET-He and its correlation with serum ferritin (SF), an index of iron stores, at 35-36 weeks postmenstrual age (PMA) in <=32 weeks gestational age (GA) infants.Methods: We performed a prospective nested study involving 24-32 weeks GA infants who were receiving 2 mg/kg/day oral elemental iron with full enteral feedings at 35-36 weeks PMA. Iron 55-59 ret proto-oncogene Homo sapiens 33-36 31662016-9 2021 RET-He increases with an increase in iron stores, suggesting that additional iron supplementation prior to discharge to very premature infants with borderline low RET-He may help prevent iron deficiency during early infancy. Iron 37-41 ret proto-oncogene Homo sapiens 0-3 31662016-9 2021 RET-He increases with an increase in iron stores, suggesting that additional iron supplementation prior to discharge to very premature infants with borderline low RET-He may help prevent iron deficiency during early infancy. Iron 77-81 ret proto-oncogene Homo sapiens 0-3 31662016-9 2021 RET-He increases with an increase in iron stores, suggesting that additional iron supplementation prior to discharge to very premature infants with borderline low RET-He may help prevent iron deficiency during early infancy. Iron 77-81 ret proto-oncogene Homo sapiens 163-166 31104454-10 2019 CONCLUSION: Children with IDA receiving iron preparations with L. reuteri DSM 17938 for 14 days show higher Ret-He levels than those receiving iron preparations alone. Iron 40-44 ret proto-oncogene Homo sapiens 108-111 31496915-0 2019 The Importance of RET-He in the Diagnosis of Iron Deficiency and Iron Deficiency Anemia and the Evaluation of Response to Oral Iron Therapy. Iron 45-49 ret proto-oncogene Homo sapiens 18-21 30140071-8 2018 Ret-He was significantly lower among iron-deficient infants, at 4 months mean difference (95% CI) -4.2 pg/L (-6.1 to -2.4) and at 12 months mean difference (95% CI) -3.4 pg/L (-5.0 to -1.8). Iron 37-41 ret proto-oncogene Homo sapiens 0-3 30140071-9 2018 CONCLUSIONS: This longitudinal study presents Ret-He reference intervals based on non-anemic and non-iron-deficient infants and constitutes a step towards standardizing Ret-He as a pre-anemia biomarker of iron deficiency in children. Iron 101-105 ret proto-oncogene Homo sapiens 46-49